All entries for: Corvus Pharmaceuticals

March 12, 2026

Corvus Pharmaceuticals

Negative Outlook

Burlingame, CA
51-200 employees

The Trump administration is pursuing a two-fold strategy to reduce drug costs in the U.S. President Trump has threatened to impose significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as most favored nation pricing, which would tie the price for drugs in the U.S. to the lowest price in a group of other countries. In response, multiple manufacturers have reportedly entered into confidential pricing agreements with the federal government. The Trump administration is also pursuing traditional regulatory pathways to impose drug pricing policies, and published two proposed regulations in December 2025, referred to as Globe and Guard…While the impact of the Globe and Guard proposed regulations, if finalized, cannot yet be determined, it is likely to be significant.

November 4, 2025

Corvus Pharmaceuticals

Neutral Outlook

Burlingame, CA
51-200 employees

While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.

Disease Area: Dermatology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
May 8, 2025

Corvus Pharmaceuticals

Neutral Outlook

Burlingame, CA
51-200 employees

While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.

Disease Area: Dermatology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
Scroll to Top